Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Sep. 30, 2026	Dec. 31, 2025
Current assets:
Cash and cash equivalents	$ 48,399	$ 64,908
Trade receivables, net	94,912	89,758
Other receivables	11,461	13,921
Inventories	107,053	92,427
Deferred preservation costs	53,730	54,531
Prepaid expenses and other	23,256	42,537
Total current assets	338,811	358,082
Goodwill	344,961	254,091
Acquired technology, net	145,901	123,664
Operating lease right-of-use assets, net	35,539	34,701
Property and equipment, net	81,728	64,988
Other intangibles, net	76,008	32,831
Deferred tax assets, net	1,273	1,201
Other long-term assets	17,867	15,238
Total assets	1,042,088	884,796
Current liabilities:
Accounts payable	17,632	16,042
Accrued compensation	18,914	22,484
Accrued expenses	17,721	16,447
Accrued interest	6,620	4,815
Taxes payable	4,095	7,489
Accrued procurement fees	1,797	3,436
Current portion of contingent consideration	0	20,690
Current maturities of operating leases	5,093	4,649
Current portion of finance lease obligations	857	726
Other current liabilities	3,926	4,778
Total current liabilities	76,655	101,556
Long-term debt, net	363,787	215,114
Non-current contingent consideration	71,100	39,890
Non-current maturities of operating leases	34,715	34,427
Deferred tax liabilities, net	24,721	24,308
Deferred compensation liability	10,687	9,464
Non-current finance lease obligations	2,575	2,698
Other long-term liabilities	11,448	9,107
Total liabilities	595,688	436,564
Commitments and contingencies
Stockholders’ equity:
Preferred stock $0.01 par value per share, 5,000 shares authorized, no shares issued	0	0
Common stock $0.01 par value per share, 75,000 shares authorized, 50,277 and 49,330 shares issued as of September 30, 2026 and December 31, 2025, respectively	503	493
Additional paid-in capital	543,517	516,604
Retained deficit	(71,517)	(51,498)
Accumulated other comprehensive loss	(11,455)	(2,719)
Treasury stock, at cost, 1,487 shares as of September 30, 2026 ‎and December 31, 2025	(14,648)	(14,648)
Total stockholders’ equity	446,400	448,232
Total liabilities and stockholders’ equity	$ 1,042,088	$ 884,796

Donated tissue is procured from deceased human donors by tissue banks and organ procurement organizations, which consign the tissue to the Company for processing, preservation, and distribution. The Company accrues estimated procurement fees due at the time tissues are received based on contractual agreements between the Company and the tissue banks and organ procurement organizations.

No definition available.